Posts tagged TIL therapy
Roth resumes coverage of Lion Biotech at buy

Roth Capital Partners has reinitiated coverage of Lion Biotechnologies (NASDAQ:LBIO) with a “buy” rating and $14 price target. The stock closed at $7.15 on Feb. 14.

Read More